EGFR is also a well-studied target in PC, and Yang et al. conducted a phase 1 clinical trial administering EGFR CAR-T cells to patients with metastatic PC and showed that the cells were safe and effective (NCT01869166) (Fig. 3). Here, EGFR is linked to pachyonychia congenita.